Loading...

Regis Healthcare Limited

REG.AXASX
Healthcare
Medical - Care Facilities
A$8.79
A$-0.01(-0.11%)

Regis Healthcare Limited (REG.AX) Financial Performance & Income Statement Overview

Explore the financials of Regis Healthcare Limited (REG.AX), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
31.44%
31.44%
Operating Income Growth
224.10%
224.10%
Net Income Growth
24.73%
24.73%
Operating Cash Flow Growth
139.91%
139.91%
Operating Margin
10.33%
10.33%
Gross Margin
17.80%
17.80%
Net Profit Margin
1.37%
1.37%
ROE
-74.75%
74.75%
ROIC
-1378.00%
1378.005%

Regis Healthcare Limited (REG.AX) Income Statement & Financial Overview

Review Regis Healthcare Limited REG.AX income statement with detailed quarterly and annual figures.

MetricQ4 2024Q2 2024Q4 2023Q2 2023
Revenue$533.98M$475.66M$394.72M$376.76M
Cost of Revenue$442.51M$459.35M$397.59M$377.68M
Gross Profit$91.47M$16.31M-$2.87M-$910000.00
Gross Profit Ratio$0.17$0.03-$0.007-$0.002
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses$36.82M$41.82M$49.15M$36.46M
Operating Expenses$36.82M$41.82M$49.15M$36.46M
Total Costs & Expenses$479.33M$501.17M$446.74M$414.13M
Interest Income$2.69M$1.29M$526000.00$179000.00
Interest Expense$50.76M$40.89M$6.13M$36.89M
Depreciation & Amortization$65.02M$63.05M$63.12M$63.35M
EBITDA$102.21M$89.24M$64.46M$62.92M
EBITDA Ratio$0.19$0.08$0.03$0.07
Operating Income$54.65M-$25.51M-$52.03M-$37.37M
Operating Income Ratio$0.10-$0.05-$0.13-$0.10
Other Income/Expenses (Net)-$68.14M-$54.74M-$30.83M-$66.11M
Income Before Tax-$13.49M-$14.61M-$3.89M-$36.49M
Income Before Tax Ratio-$0.03-$0.03-$0.010-$0.10
Income Tax Expense-$4.22M-$2.47M-$1.35M-$10.58M
Net Income-$9.27M-$12.14M-$2.54M-$25.91M
Net Income Ratio-$0.02-$0.03-$0.006-$0.07
EPS-$0.03-$0.04-$0.008-$0.09
Diluted EPS-$0.03-$0.04-$0.008-$0.09
Weighted Avg Shares Outstanding$301.06M$300.98M$300.91M$300.87M
Weighted Avg Shares Outstanding (Diluted)$301.10M$300.98M$300.91M$300.87M

Over the past four quarters, Regis Healthcare Limited demonstrated steady revenue growth, increasing from $376.76M in Q2 2023 to $533.98M in Q4 2024. Operating income reached $54.65M in Q4 2024, maintaining a consistent 10% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $102.21M, reflecting operational efficiency. Net income rose to -$9.27M, with EPS at -$0.03. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;